ArticleJournal of clinical biochemistry and nutrition2013
Isoflavone metabolism and bone-sparing effects of daidzein-metabolites.
Article in Journal of clinical biochemistry and nutrition, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Soybean Synergies: A Comprehensive Review on Novel Extraction Techniques and Their Role in Unlocking Health Potential.Food science & nutrition · 2025Review
- Exploring the Complex Mechanisms of Isoflavones: From Cell Bioavailability, to Cell Dynamics and Breast Cancer.Phytotherapy research : PTR · 2025Review
- Exploring the anti-aging potential of phytoestrogens: focus on molecular mechanisms and menopausal symptom modulation.Frontiers in nutrition · 2025Review
- A mixture ofHeliyon · 2024Article
- Biotransformation of Natural Products and Phytochemicals: Metabolites, Their Preparation, and Properties.International journal of molecular sciences · 2023Article
- Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review.Frontiers in pharmacology · 2022Review
- Deep Learning-Assisted Repurposing of Plant Compounds for Treating Vascular Calcification: An In Silico Study with Experimental Validation.Oxidative medicine and cellular longevity · 2022Article
- Article
- The Effects ofNutrients · 2020Article
- Evaluation of Isoflavones as Bone Resorption Inhibitors upon Interactions with Receptor Activator of Nuclear Factor-κB Ligand (RANKL).Molecules (Basel, Switzerland) · 2020Article
- Nutrikinetics of Isoflavone Metabolites After Fermented Soybean Product (Cheonggukjang) Ingestion in Ovariectomized Mice.Molecular nutrition & food research · 2017Article
- Review
- Equol, a Dietary Daidzein Gut Metabolite Attenuates Microglial Activation and Potentiates Neuroprotection In Vitro.Nutrients · 2017Article
- Influence of Oral and Gut Microbiota in the Health of Menopausal Women.Frontiers in microbiology · 2017Review
- Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis.Bone research · 2017Review
- The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol.Metabolites · 2015Review
- EFFECT OF PUERARIN ON THE PROLIFERATION AND DIFFERENTIATION OF OSTEOBLASTS AND THE EXPRESSION OF TYPE I COLLAGEN mRNA IN A HIGH-GLUCOSE ENVIRONMENT.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several dietary phytochemicals exhibit anti-oxidative, anti-inflammatory and anti-osteoporotic activities relevant to prevention of chronic diseases, including lifestyle-related diseases. Soybean isoflavones are similar in structure to estrogen and have received considerable attention as potential alternatives to hormone replacement therapy. Daidzein, a major isoflavone found in soybean, is metabolized to equol by intestinal microflora; this metabolite exhibits stronger estrogenic activity than daidzein. Recent studies suggest that the clinical effectiveness of isoflavones might be due to their ability to produce equol in the gut. This review focused on the metabolic pathway of equol and possible bioactivities of equol and O-desmethylangolensin, another metabolite of daidzein, with regard to bone metabolism and the status of intestinal microflora. Furthermore, we considered risk-benefit analyses of isoflavones and their metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.